Everything you need to know about the monkeypox vaccination



eitb media

The Basque Autonomous Community has started vaccinating against monkeypox and has received 141 doses, with distribution to be made according to population and number of cases.

Read in Basque: Everything you need to know about the monkeypox vaccination

The Basque Autonomous Community began this Monday to vaccinate against monkeypox and has 141 servingsthat Osakidetza will distribute among the historical territories according to the number of inhabitants.

A) Yes, Biscay will receive 80 doses (57%), Gipuzkoa46 (33%) y Alavameanwhile, 14 doses (ten%).

Next, we review the keys and the main doubts about this vaccine collected by the Ministry of Health of the Basque Government.

• Is there a monkeypox vaccine?

Yes, there is a new vaccine that contains a modified virus that cannot cause disease or transmit it to other people.

The European Commission approved vaccine available to prevent monkeypox infection is IMVANEX (also known as IMVAMUNE or JYNNEOS).

There is a limitation of the current supply, although more are expected in the coming months. Initially, one dose will be administered and the regimen will be completed when the vaccine becomes available.

• How is the vaccine accessible?

While the availability of vaccines is limited, Osakidetza will contact eligible people to invite them to participate in the vaccination campaign, according to the criteria approved by the public health commission.

• What are the criteria for use?

– Pre-exposure intended for people aged 18 to 45 who meet the following criteria: engage in risky sexual practices.

– Not having had the disease before.

– Not having previously received smallpox vaccine.

– Post-exposure (within the first 14 days after contact) directed to close contacts of a confirmed case at high risk of serious illness: pregnant women.

– Population of children.

– Immunocompromised people.

• What effects does the vaccine have?

It is a safe vaccine. The side effects that may occur are similar to those of other vaccines; pain, redness at the injection site, headache or muscle pain. They are light and short-lived.

Data on the effectiveness of this vaccine in the current epidemic are not yet available.

To better understand the benefits of these vaccines in the current outbreak, safety data on potential adverse events and efficacy data will be collected to understand the level of protection offered by the vaccine.

Leave a Comment